Dernière mise à jour : 02 septembre 2016
Détails
FichiersGeneric Name:
Pomalidomide
État du projet:
Terminé
Domaine thérapeutique:
Multiple Myeloma
Fabricant:
Celgene Inc.
Brand Name:
Pomalyst
Gamme de produits:
Examen en vue du remboursement
Numéro de projet :
PC0036-000
Indicateur de rendement:
S. O. – Mesures de rendement prédictives
Strength:
1, 2, 3, 4 mg capsules
Tumour Type:
Myeloma
Indications:
Multiple Myeloma
Funding Request:
In combination with low-dose dexamethasone for patients with multiple myeloma for whom both bortezomib and lenalidomide have failed and who have received at least two prior treatment regimens and have demonstrated disease progression on the last regimen
Review Status:
Complete
Pre Noc Submission:
Yes
Date NOC Issued:
Sponsor:
Celgene Inc.
Submission Date:
Submission Deemed Complete:
Priorisation demandée:
Non demandée
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommandation:
Remboursement sous critères cliniques ou conditions
pERC Meeting:
Final Recommendation Issued:
Fichiers
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Dernière mise à jour : 02 septembre 2016